首页 > 最新文献

Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology, head, and neck surgery最新文献

英文 中文
[Analysis of efficacy and prognosis of neoadjuvant chemotherapy and (or) surgery plus radiotherapy for hypopharyngeal squamous cell carcinoma]. [新辅助化疗和(或)手术加放疗治疗下咽鳞癌的疗效和预后分析手术加放疗治疗下咽鳞状细胞癌的疗效和预后分析]。
Q4 Medicine Pub Date : 2023-09-01 DOI: 10.13201/j.issn.2096-7993.2023.09.004
Qihui Xiao, Pin Dong, Xinwei Chen, Xingjiang Ying, Yuyin Liu, Lixiao Chen, Jian Ding

Objective:To analyze the risk factors that affect the prognosis of patients with hypopharyngeal squamous cell carcinoma(HPSCC) and to compare the efficacy of surgical resection followed by adjuvant radiotherapy(SR) with that of neoadjuvant therapy consisting of platinum-based chemotherapy and fluorouracil combined with either cetuximab or nimotuzumab, followed by SR. The study also aimed to evaluate the overall survival(OS) of patients, their postoperative eating function, tracheostomy decannulation rate, and tumor response to the two neoadjuvant chemotherapies. Methods:A retrospective analysis was performed on the medical records of HPSCC patients who received SR or neoadjuvant therapy followed by SR treatment at the Shanghai General Hospital from 2012 to 2019 and had not undergone any prior treatment. The prognostic factors were analyzed, and the survival analysis of patients who underwent SR treatment with two neoadjuvant chemotherapy regimens was performed. Results:A total of 108 patients were included in the study. The results of the univariate analysis showed that gender(P=0.850) had no significant correlation with the survival rate of HPSCC patients who underwent SR. However, age, smoking history, alcohol consumption history, platelet-to-lymphocyte ratio(PLR), neutrophil-to-lymphocyte ratio(NLR), T stage, N stage, neoadjuvant therapy with either cetuximab or nimotuzumab combined with platinum-based chemotherapy and fluorouracil, and histological grade were significantly associated with prognosis(P<0.05). The multivariate analysis revealed that smoking history, histological grade, and neoadjuvant therapy with either cetuximab or nimotuzumab combined with platinum-based chemotherapy and fluorouracil were independent risk factors affecting the prognosis of HPSCC(P<0.05). Patients who received neoadjuvant therapy had longer OS than those who underwent SR only(P<0.001). There was no significant difference in tumor response to the two neoadjuvant therapies and in OS(P>0.05), and there was no significant difference in the rate of oral feeding and tracheostomy decannulation among the three treatment groups(P>0.05). Conclusion:Univariate analysis showed that age at tumor onset, smoking history, alcohol consumption history, NLR, PLR, T stage, N stage, whether receiving neoadjuvant chemotherapy, and pathological grade were associated with the prognosis of HPSCC patients receiving SR treatment. Multivariate analysis showed that smoking history, pathological grade, and neoadjuvant chemotherapy were independent risk factors affecting the prognosis. Neoadjuvant chemotherapy with cetuximab or nimotuzumab can prolong the OS of patients, providing a certain basis and reference for the treatment of HPSCC.

目的:分析影响下咽鳞状细胞癌(HPSCC)患者预后的危险因素,比较手术切除后辅助放疗(SR)的疗效。的疗效进行比较。与新辅助治疗(包括铂类化疗和氟尿嘧啶联合西妥昔单抗或尼莫妥珠单抗,然后进行SR)的疗效进行比较。研究还旨在评估患者的总生存率(OS)患者的总生存率(OS)、术后进食功能、气管切开率以及肿瘤对两种新辅助化疗的反应。方法:对2012年至2019年期间在上海总医院接受SR治疗或新辅助治疗后再接受SR治疗的HPSCC患者的病历进行回顾性分析。分析了预后因素,并对接受两种新辅助化疗方案SR治疗的患者进行了生存分析。结果:研究共纳入108例患者。单变量分析结果显示,性别(P=0.850)与接受SR治疗的HPSCC患者的生存率无明显相关性。然而,年龄、吸烟史、饮酒史、血小板与淋巴细胞比值(PLR)、中性粒细胞与淋巴细胞比值(NLR)、T分期、N分期、西妥昔单抗或尼莫妥珠单抗联合铂类化疗和氟尿嘧啶的新辅助治疗以及组织学分级与预后显著相关(PPPP>0.05),三组患者的口服喂养率和气管切开率差异无学意义(P>0.05)。结论:单变量分析显示,肿瘤发生年龄、吸烟史、饮酒史、NLR、PLR、T分期、N分期、是否接受新辅助化疗以及病理分级与接受SR治疗的HPSCC患者的预后有关。多变量分析显示,吸烟史、病理分级和新辅助化疗是影响预后的独立危险因素。西妥昔单抗或尼莫妥珠单抗的新辅助化疗可延长患者的OS,为HPSCC的治疗提供了一定的依据和参考。
{"title":"[Analysis of efficacy and prognosis of neoadjuvant chemotherapy and (or) surgery plus radiotherapy for hypopharyngeal squamous cell carcinoma].","authors":"Qihui Xiao, Pin Dong, Xinwei Chen, Xingjiang Ying, Yuyin Liu, Lixiao Chen, Jian Ding","doi":"10.13201/j.issn.2096-7993.2023.09.004","DOIUrl":"10.13201/j.issn.2096-7993.2023.09.004","url":null,"abstract":"<p><p><b>Objective:</b>To analyze the risk factors that affect the prognosis of patients with hypopharyngeal squamous cell carcinoma(HPSCC) and to compare the efficacy of surgical resection followed by adjuvant radiotherapy(SR) with that of neoadjuvant therapy consisting of platinum-based chemotherapy and fluorouracil combined with either cetuximab or nimotuzumab, followed by SR. The study also aimed to evaluate the overall survival(OS) of patients, their postoperative eating function, tracheostomy decannulation rate, and tumor response to the two neoadjuvant chemotherapies. <b>Methods:</b>A retrospective analysis was performed on the medical records of HPSCC patients who received SR or neoadjuvant therapy followed by SR treatment at the Shanghai General Hospital from 2012 to 2019 and had not undergone any prior treatment. The prognostic factors were analyzed, and the survival analysis of patients who underwent SR treatment with two neoadjuvant chemotherapy regimens was performed. <b>Results:</b>A total of 108 patients were included in the study. The results of the univariate analysis showed that gender(<i>P</i>=0.850) had no significant correlation with the survival rate of HPSCC patients who underwent SR. However, age, smoking history, alcohol consumption history, platelet-to-lymphocyte ratio(PLR), neutrophil-to-lymphocyte ratio(NLR), T stage, N stage, neoadjuvant therapy with either cetuximab or nimotuzumab combined with platinum-based chemotherapy and fluorouracil, and histological grade were significantly associated with prognosis(<i>P</i><0.05). The multivariate analysis revealed that smoking history, histological grade, and neoadjuvant therapy with either cetuximab or nimotuzumab combined with platinum-based chemotherapy and fluorouracil were independent risk factors affecting the prognosis of HPSCC(<i>P</i><0.05). Patients who received neoadjuvant therapy had longer OS than those who underwent SR only(<i>P</i><0.001). There was no significant difference in tumor response to the two neoadjuvant therapies and in OS(<i>P</i>>0.05), and there was no significant difference in the rate of oral feeding and tracheostomy decannulation among the three treatment groups(<i>P</i>>0.05). <b>Conclusion:</b>Univariate analysis showed that age at tumor onset, smoking history, alcohol consumption history, NLR, PLR, T stage, N stage, whether receiving neoadjuvant chemotherapy, and pathological grade were associated with the prognosis of HPSCC patients receiving SR treatment. Multivariate analysis showed that smoking history, pathological grade, and neoadjuvant chemotherapy were independent risk factors affecting the prognosis. Neoadjuvant chemotherapy with cetuximab or nimotuzumab can prolong the OS of patients, providing a certain basis and reference for the treatment of HPSCC.</p>","PeriodicalId":18104,"journal":{"name":"Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology, head, and neck surgery","volume":"37 9","pages":"700-707"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10722116/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10120011","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Comprehensive treatment strategies for head neck tumors]. 【头颈部肿瘤综合治疗策略】。
Q4 Medicine Pub Date : 2023-09-01 DOI: 10.13201/j.issn.2096-7993.2023.09.001
Zhigang Huang, Weiping Wen, Wei Mao
{"title":"[Comprehensive treatment strategies for head neck tumors].","authors":"Zhigang Huang, Weiping Wen, Wei Mao","doi":"10.13201/j.issn.2096-7993.2023.09.001","DOIUrl":"10.13201/j.issn.2096-7993.2023.09.001","url":null,"abstract":"","PeriodicalId":18104,"journal":{"name":"Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology, head, and neck surgery","volume":"37 9","pages":"673-690"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10722124/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10175351","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Diffuse large B-cell lymphoma of thyroid invading the superior mediastinum with hashimoto's thyroiditis: a case report and literature review]. [甲状腺弥漫性大B细胞淋巴瘤侵犯上纵隔并伴有桥本氏甲状腺炎:病例报告和文献综述]。
Q4 Medicine Pub Date : 2023-09-01 DOI: 10.13201/j.issn.2096-7993.2023.09.012
Jiamu Lv, Tingting Yu, Wanzhong Yin

This article reports a case of primary thyroid diffuse large B-cell lymphoma involving the superior mediastinum with Hashimoto's thyroiditis admitted to the Department of Otolaryngology and Head and Neck Surgery, First Hospital of Jilin University. This patient underwent right thyroid lobectomy and was transferred to the Department of Hematology of the Oncology Center for 6 courses of chemotherapy with R-CHOP protocol. The postoperative recovery was good, and the patient was regularly followed up for 12 months after the operation. The patient's condition was stable, and CT showed no abnormally high metabolism in the operation area indicating the inhibition of tumor activity, superficial lymph nodes and peripheral blood cells were normal. The case encountered many difficulties in the diagnosis process, and the diagnosis was not confirmed after puncture in two Grade III Class A hospitals in China. There are few patients with primary thyroid diffuse large B-cell lymphoma complicated with Hashimoto's thyroiditis, and it is particularly rare to invade the mediastinum. There is no report in China and abroad in the literature we reviewed. Therefore, this article reports the case and retrospectively analyzes the etiology, clinical symptoms, diagnosis and treatment of primary thyroid lymphoma.

本文报道了吉林大学第一医院耳鼻咽喉头颈外科收治的一例原发性甲状腺弥漫大B细胞淋巴瘤累及上纵隔并伴有桥本氏甲状腺炎的患者。该患者接受了右甲状腺叶切除术,并转入肿瘤中心血液科接受了6个疗程的R-CHOP方案化疗。术后恢复良好,术后定期随访12个月。患者病情稳定,CT显示术区代谢无异常增高,提示肿瘤活性已被抑制,浅表淋巴结及外周血细胞正常。该病例在诊断过程中遇到了很多困难,在国内两家三级甲等医院穿刺后均未确诊。原发性甲状腺弥漫大B细胞淋巴瘤并发桥本氏甲状腺炎的患者很少,尤其是侵犯纵膈的患者更是罕见。在我们查阅的文献中,国内外均无相关报道。因此,本文报告了该病例,并对原发性甲状腺淋巴瘤的病因、临床症状、诊断和治疗进行了回顾性分析。
{"title":"[Diffuse large B-cell lymphoma of thyroid invading the superior mediastinum with hashimoto's thyroiditis: a case report and literature review].","authors":"Jiamu Lv, Tingting Yu, Wanzhong Yin","doi":"10.13201/j.issn.2096-7993.2023.09.012","DOIUrl":"10.13201/j.issn.2096-7993.2023.09.012","url":null,"abstract":"<p><p><b></b> This article reports a case of primary thyroid diffuse large B-cell lymphoma involving the superior mediastinum with Hashimoto's thyroiditis admitted to the Department of Otolaryngology and Head and Neck Surgery, First Hospital of Jilin University. This patient underwent right thyroid lobectomy and was transferred to the Department of Hematology of the Oncology Center for 6 courses of chemotherapy with R-CHOP protocol. The postoperative recovery was good, and the patient was regularly followed up for 12 months after the operation. The patient's condition was stable, and CT showed no abnormally high metabolism in the operation area indicating the inhibition of tumor activity, superficial lymph nodes and peripheral blood cells were normal. The case encountered many difficulties in the diagnosis process, and the diagnosis was not confirmed after puncture in two Grade III Class A hospitals in China. There are few patients with primary thyroid diffuse large B-cell lymphoma complicated with Hashimoto's thyroiditis, and it is particularly rare to invade the mediastinum. There is no report in China and abroad in the literature we reviewed. Therefore, this article reports the case and retrospectively analyzes the etiology, clinical symptoms, diagnosis and treatment of primary thyroid lymphoma.</p>","PeriodicalId":18104,"journal":{"name":"Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology, head, and neck surgery","volume":"37 9","pages":"755-758"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10722120/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10175347","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[The application of transcervical non-inflatable endoscopic posterior inferior sternocleidomastoid approach in thyroid surgery]. [经颈椎非充气内窥镜胸锁乳突后下入路在甲状腺手术中的应用]。
Q4 Medicine Pub Date : 2023-09-01 DOI: 10.13201/j.issn.2096-7993.2023.09.002
Yixin Jing, Yiming Ding, Jing Zhou, Jun Wu, Hongfei Liu, Junwei Huang, Xiao Chen, Zhigang Huang, Xiaohong Chen

Objective:To investigate the clinical efficacy and safety of transcervical non-inflatable endoscopic thyroidectomy through the posterior inferior sternocleidomastoid approach. Methods:From December 2022 to May 2023, the clinical data of 35 patients with papillary thyroid carcinoma treated by transcervical non-inflatable endoscopic surgery via posterior inferior sternocleidomastoid approach were retrospectively analyzed. There were 14 males and 21 females, with an average age of 44.7 years. The operation time, bleeding volume, postoperative recovery, complications and follow-up were recorded. Results:All 35 patients successfully completed the surgery, with an average operation time of 4 hours and 7 minutes, an average bleeding volume of 14 ml, and an average postoperative hospital stay of 3.5 days. There were no serious complications and no obvious neck discomfort during postoperative follow-up. Conclusion:Transcervical non-inflatable endoscopic thyroidectomy via posterior inferior sternocleidomastoid approach is safe and effective, with fast postoperative recovery,high appearance satisfaction and good neck comfort.

目的:探讨经胸锁乳突肌后方下入路的经颈部非充气内镜甲状腺切除术的临床疗效和安全性。方法:回顾性分析2022年12月至2023年5月期间,35例经胸锁乳突肌后下入路的经颈部非充气内镜甲状腺乳头状癌患者的临床资料。其中男性 14 例,女性 21 例,平均年龄 44.7 岁。记录了手术时间、出血量、术后恢复、并发症和随访情况。结果:35 名患者均顺利完成手术,平均手术时间为 4 小时 7 分钟,平均出血量为 14 毫升,术后平均住院时间为 3.5 天。无严重并发症,术后随访无明显颈部不适。结论:经后胸锁乳突下入路的经颈部非充气内镜甲状腺切除术安全有效,术后恢复快,外观满意度高,颈部舒适度好。
{"title":"[The application of transcervical non-inflatable endoscopic posterior inferior sternocleidomastoid approach in thyroid surgery].","authors":"Yixin Jing, Yiming Ding, Jing Zhou, Jun Wu, Hongfei Liu, Junwei Huang, Xiao Chen, Zhigang Huang, Xiaohong Chen","doi":"10.13201/j.issn.2096-7993.2023.09.002","DOIUrl":"10.13201/j.issn.2096-7993.2023.09.002","url":null,"abstract":"<p><p><b>Objective:</b>To investigate the clinical efficacy and safety of transcervical non-inflatable endoscopic thyroidectomy through the posterior inferior sternocleidomastoid approach. <b>Methods:</b>From December 2022 to May 2023, the clinical data of 35 patients with papillary thyroid carcinoma treated by transcervical non-inflatable endoscopic surgery via posterior inferior sternocleidomastoid approach were retrospectively analyzed. There were 14 males and 21 females, with an average age of 44.7 years. The operation time, bleeding volume, postoperative recovery, complications and follow-up were recorded. <b>Results:</b>All 35 patients successfully completed the surgery, with an average operation time of 4 hours and 7 minutes, an average bleeding volume of 14 ml, and an average postoperative hospital stay of 3.5 days. There were no serious complications and no obvious neck discomfort during postoperative follow-up. <b>Conclusion:</b>Transcervical non-inflatable endoscopic thyroidectomy via posterior inferior sternocleidomastoid approach is safe and effective, with fast postoperative recovery,high appearance satisfaction and good neck comfort.</p>","PeriodicalId":18104,"journal":{"name":"Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology, head, and neck surgery","volume":"37 9","pages":"691-694"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10722125/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10175350","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Research progress on the treatment improvement of HPV-associated oropharyngeal cancer]. [改善人乳头瘤病毒相关口咽癌治疗的研究进展]。
Q4 Medicine Pub Date : 2023-09-01 DOI: 10.13201/j.issn.2096-7993.2023.09.010
Shuqi Zhao, Zhengxue Han

The number of new cases of oropharyngeal cancer is increasing year by year among the world, and HPV infection is one of the risk factors for this malignant tumor. Compared with HPV-negative oropharyngeal cancer, HPV-positive patients are more sensitive to radiotherapy and have a better prognosis, but there is no accepted treatment for HPV-positive patients. Reducing treatment intensity moderately and exploring the best option to minimize side effects of treatment are urgent issues to be addressed. This article reviews the research progress on the treatment improvement of HPV-associated oropharyngeal cancer in recent years.

全球口咽癌新发病例逐年增加,HPV 感染是这种恶性肿瘤的危险因素之一。与HPV阴性口咽癌相比,HPV阳性患者对放疗更敏感,预后更好,但目前尚无针对HPV阳性患者的公认治疗方法。适度降低治疗强度,探索减少治疗副作用的最佳方案,是目前亟待解决的问题。本文回顾了近年来在改善HPV相关口咽癌治疗方面的研究进展。
{"title":"[Research progress on the treatment improvement of HPV-associated oropharyngeal cancer].","authors":"Shuqi Zhao, Zhengxue Han","doi":"10.13201/j.issn.2096-7993.2023.09.010","DOIUrl":"10.13201/j.issn.2096-7993.2023.09.010","url":null,"abstract":"<p><p><b></b> The number of new cases of oropharyngeal cancer is increasing year by year among the world, and HPV infection is one of the risk factors for this malignant tumor. Compared with HPV-negative oropharyngeal cancer, HPV-positive patients are more sensitive to radiotherapy and have a better prognosis, but there is no accepted treatment for HPV-positive patients. Reducing treatment intensity moderately and exploring the best option to minimize side effects of treatment are urgent issues to be addressed. This article reviews the research progress on the treatment improvement of HPV-associated oropharyngeal cancer in recent years.</p>","PeriodicalId":18104,"journal":{"name":"Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology, head, and neck surgery","volume":"37 9","pages":"740-747"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10722123/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10120010","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Research progress in diagnosis and treatment of HPV-associated oropharyngeal squamous cell carcinoma]. [与人乳头瘤病毒相关的口咽鳞状细胞癌的诊断和治疗研究进展]。
Q4 Medicine Pub Date : 2023-09-01 DOI: 10.13201/j.issn.2096-7993.2023.09.009
Meilin He, Junlin Yi

Oropharyngeal carcinoma is one of the most common malignant tumors of head and neck. In recent years, the incidence of Human papilloma virus-associated oropharyngeal squamous cell carcinoma(HPV-OPSCC) has been increasing year by year. With the advancement of minimally invasive surgical techniques, the wide application of intensity modulated radiation therapy, and the demand of patients for organ function protection and higher quality of life, the unique biological behavior and better prognosis of HPV-OPSCC have led to the exploration of a series of attenuated treatment modes. This article reviews the diagnosis and treatment status of oropharyngeal cancer and related research progress based on relevant reports.

口咽癌是头颈部最常见的恶性肿瘤之一。近年来,人乳头瘤病毒相关口咽鳞癌(HPV-OPSCC)的发病率逐年上升。发病率逐年上升。随着微创外科技术的进步、调强放射治疗的广泛应用,以及患者对器官功能保护和提高生活质量的要求,HPV-OPSCC独特的生物学行为和较好的预后促使人们探索一系列减毒治疗模式。本文根据相关报道回顾了口咽癌的诊治现状及相关研究进展。
{"title":"[Research progress in diagnosis and treatment of HPV-associated oropharyngeal squamous cell carcinoma].","authors":"Meilin He, Junlin Yi","doi":"10.13201/j.issn.2096-7993.2023.09.009","DOIUrl":"10.13201/j.issn.2096-7993.2023.09.009","url":null,"abstract":"<p><p><b></b> Oropharyngeal carcinoma is one of the most common malignant tumors of head and neck. In recent years, the incidence of Human papilloma virus-associated oropharyngeal squamous cell carcinoma(HPV-OPSCC) has been increasing year by year. With the advancement of minimally invasive surgical techniques, the wide application of intensity modulated radiation therapy, and the demand of patients for organ function protection and higher quality of life, the unique biological behavior and better prognosis of HPV-OPSCC have led to the exploration of a series of attenuated treatment modes. This article reviews the diagnosis and treatment status of oropharyngeal cancer and related research progress based on relevant reports.</p>","PeriodicalId":18104,"journal":{"name":"Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology, head, and neck surgery","volume":"37 9","pages":"734-739"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10722117/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10175354","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[TCOF1 Gene variation in Treacher Collins syndrome and evaluation of speech rehabilitation after bone bridge surgery]. [特雷撤-科林斯症候群的 TCOF1 基因变异与骨桥手术后的语言康复评估]。
Q4 Medicine Pub Date : 2023-09-01 DOI: 10.13201/j.issn.2096-7993.2023.09.011
Yonghua Li, Wenyue Chi, Ken Lin, Jinyan Zu, Hua Shao, Zhiyong Mao, Quandong Chen, Jing Ma

Objective:By analyzing the clinical phenotypic characteristics and gene sequences of two patients with Treacher Collins syndrome(TCS), the biological causes of the disease were determined. Then discuss the therapeutic effect of hearing intervention after bone bridge implantation. Methods:All clinical data of the two family members were collected, and the patients signed the informed consent. The peripheral blood of the proband and family members was extracted, DNA was extracted for whole exome sequencing, and Sanger sequencing was performed on the family members for the mutation site.TCOF1genetic mutations analysis was performed on the paitents. Then, the hearing threshold and speech recognition rate of family 2 proband were evaluated and compared under the sound field between bare ear and wearing bone bridge. Results:In the two pedigrees, the probands of both families presented with auricle deformity, zygomatic and mandibular hypoplasia, micrognathia, hypotropia of the eye fissure, and hypoplasia of the medial eyelashes. The proband of Family 1 also presents with specific features including right-sided narrow anterior nasal aperture and dental hypoplasia, which were consistent with the clinical diagnosis of Treacher Collins syndrome. Genetic testing was conducted on both families, and two heterozygous mutations were identified in the TCOF1 gene: c. 1350_1351dupGG(p. A451Gfs*43) and c. 4362_4366del(p. K1457Efs*12), resulting in frameshift mutations in the amino acid sequence. Sanger sequencing validation of the TCOF1 gene in the parents of the proband in Family 1 did not detect any mutations. Proband 1 TCOF1 c. 1350_1351dupGG heterozygous variants have not been reported previously. The postoperative monosyllabic speech recognition rate of family 2 proband was 76%, the Categories of Auditory Performance(CAP) score was 6, and the Speech Intelligibility Rating(SIR) score was 4. Assessment using the Meaningful Auditory Integration Scale(MAIS) showed notable improvement in the patient's auditory perception, comprehension, and usage of hearing aids. Evaluation using the Glasgow Children's Benefit Inventory and quality of life assessment revealed significant improvements in the child's self care abilities, daily living and learning, social interactions, and psychological well being, as perceived by the parents. Conclusion:This study has elucidated the biological cause of Treacher Collins syndrome, enriched the spectrum of TCOF1 gene mutations in the Chinese population, and demonstrated that bone bridge implantation can improve the auditory and speech recognition rates in TCS patients.

目的:通过分析两名特雷撤-科林斯综合征(TCS)患者的临床表型特征和基因序列,确定该病的生物学病因。然后探讨骨桥植入术后听力干预的治疗效果。方法:收集两个家族成员的所有临床资料,患者签署知情同意书。对患者进行TCOF1基因突变分析。然后,对家族 2 的听阈和言语识别率进行了评估,并比较了裸耳和佩戴骨桥在声场下的听阈和言语识别率。结果:在这两个家系中,两个家系的原发病均表现为耳廓畸形、颧骨和下颌骨发育不良、小颌畸形、眼裂变小和内侧睫毛发育不良。家族 1 的原告也有一些特殊的特征,包括右侧狭窄的前鼻孔和牙齿发育不全,这与特雷撤-科林斯综合征的临床诊断一致。对这两个家庭进行了基因检测,在 TCOF1 基因中发现了两个杂合突变:c. 1350_1351dupGG(p. A451Gfs*43)和 c. 1350_1351dupGG(p. A451Gfs*43)。A451Gfs*43)和 c.和 c. 4362_4366del(p.K1457Efs*12),导致氨基酸序列发生框架移位突变。对家族 1 中疑似患者父母的 TCOF1 基因进行的 Sanger 测序验证未检测到任何突变。前带 1 TCOF1 c. 1350_1351dupGG 杂合子变异此前未见报道。家族 2 患儿术后单音节语音识别率为 76%,听觉表现分类(CAP)得分为 6 分,言语智能测试(SP)得分为 5 分。评分为6分,语音清晰度评分(SIR)为4分。使用有意义听觉整合量表(MAIS)进行的评估显示,患者的听觉功能明显改善。结果显示,患者的听觉感知能力、理解能力和助听器使用情况都有明显改善。使用格拉斯哥儿童受益量表和生活质量评估进行的评估显示,儿童的自理能力、日常生活和学习能力、社会交往能力以及家长认为的心理健康水平均有显著改善。结论:本研究阐明了特雷撤-科林斯综合征的生物学病因,丰富了中国人群中TCOF1基因突变的谱系,并证明骨桥植入术可提高特雷撤-科林斯综合征患者的听觉和言语识别率。
{"title":"[<i>TCOF1</i> Gene variation in Treacher Collins syndrome and evaluation of speech rehabilitation after bone bridge surgery].","authors":"Yonghua Li, Wenyue Chi, Ken Lin, Jinyan Zu, Hua Shao, Zhiyong Mao, Quandong Chen, Jing Ma","doi":"10.13201/j.issn.2096-7993.2023.09.011","DOIUrl":"10.13201/j.issn.2096-7993.2023.09.011","url":null,"abstract":"<p><p><b>Objective:</b>By analyzing the clinical phenotypic characteristics and gene sequences of two patients with Treacher Collins syndrome(TCS), the biological causes of the disease were determined. Then discuss the therapeutic effect of hearing intervention after bone bridge implantation. <b>Methods:</b>All clinical data of the two family members were collected, and the patients signed the informed consent. The peripheral blood of the proband and family members was extracted, DNA was extracted for whole exome sequencing, and Sanger sequencing was performed on the family members for the mutation site.<i>TCOF1</i>genetic mutations analysis was performed on the paitents. Then, the hearing threshold and speech recognition rate of family 2 proband were evaluated and compared under the sound field between bare ear and wearing bone bridge. <b>Results:</b>In the two pedigrees, the probands of both families presented with auricle deformity, zygomatic and mandibular hypoplasia, micrognathia, hypotropia of the eye fissure, and hypoplasia of the medial eyelashes. The proband of Family 1 also presents with specific features including right-sided narrow anterior nasal aperture and dental hypoplasia, which were consistent with the clinical diagnosis of Treacher Collins syndrome. Genetic testing was conducted on both families, and two heterozygous mutations were identified in the <i>TCOF1</i> gene: c. 1350_1351dupGG(p. A451Gfs*43) and c. 4362_4366del(p. K1457Efs*12), resulting in frameshift mutations in the amino acid sequence. Sanger sequencing validation of the <i>TCOF1</i> gene in the parents of the proband in Family 1 did not detect any mutations. Proband 1 <i>TCOF1</i> c. 1350_1351dupGG heterozygous variants have not been reported previously. The postoperative monosyllabic speech recognition rate of family 2 proband was 76%, the Categories of Auditory Performance(CAP) score was 6, and the Speech Intelligibility Rating(SIR) score was 4. Assessment using the Meaningful Auditory Integration Scale(MAIS) showed notable improvement in the patient's auditory perception, comprehension, and usage of hearing aids. Evaluation using the Glasgow Children's Benefit Inventory and quality of life assessment revealed significant improvements in the child's self care abilities, daily living and learning, social interactions, and psychological well being, as perceived by the parents. <b>Conclusion:</b>This study has elucidated the biological cause of Treacher Collins syndrome, enriched the spectrum of <i>TCOF1</i> gene mutations in the Chinese population, and demonstrated that bone bridge implantation can improve the auditory and speech recognition rates in TCS patients.</p>","PeriodicalId":18104,"journal":{"name":"Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology, head, and neck surgery","volume":"37 9","pages":"748-754"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10722122/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10122070","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Clinical characteristics and efficacy of oropharyngeal carcinoma with secondary primary tumor]. [口咽癌继发原发肿瘤的临床特点和疗效]。
Q4 Medicine Pub Date : 2023-09-01 DOI: 10.13201/j.issn.2096-7993.2023.09.007
Meilin He, Runye Wu, Ye Zhang, Xiaodong Huang, Kai Wang, Xuesong Chen, Jingbo Wang, Yuan Qu, Jingwei Luo, Junlin Yi

Objective:To analysis the clinical features and prognosis in oropharyngeal carcinoma with secondary primary tumor. Methods:A retrospective analysis was performed on 468 pathologically confirmed oropharyngeal cancer as the primary tumor patients with p16 status, excluded distant metastasis, and admitted to the Chinese Academy of Medical Sciences from January 2010 to December 2020. The clinical features and prognosis of the secondary primary tumor were analyzed. Results:Among 468 patients with oropharyngeal cancer treated at initial diagnosed, 222 cases were P16-negative. With a median follow-up time of 64.3 months, 66 cases developed second primary cancer, with an incidence of 29.3%, among which 63.6%(42/66) were synchronous and 36.4%(24/66) were heterochronous, esophagus was the most commonly involved site. The 5-year OS of p16-negative oropharyngeal carcinoma with synchronous second primary cancer, without second primary cancer and with heterogeneous second primary cancer were 26.3% and 57.3% and 73.2%(P=0.001); The second primary cancer accounted for 11.2%(12/107) of the deaths in the whole group, among them, the heterochronous second primary accounted for 75.0%(9/12). There were 246 patients with p16 positive, with a median follow-up time of 52.4 months, 20 patients developed second primary cancer(8.1%). Among them, 65.0%(13/20) were synchronous and 35.0%(7/20) were heterochronous. Esophagus was the most commonly involved site. The 4-year OS of p16-positive with synchronous, heterochronous and non-second primary cancer group were 51.9%, 80.7% and 83.3%. Secondary primary cancer accounted for 3.8%(2/52) of all deaths in p16 positvie group. Conclusion:The incidence of second primary cancer of p16 positive and negative oropharyngeal carcinoma were different. The esophagus was the most commonly involved site regardless of p16 status. Regardless of p16 status, the survival of patients with synchronous second primary cancer was worse than those without second primary cancer. For p16-negative oropharyngeal carcinoma, the prognosis was better in patients with heterogeneous second primary cancer, the second primary cancer is one of the main causes of death.

目的:分析口咽癌继发原发肿瘤的临床特征和预后。方法:对中国医学科学院2010年1月至2020年12月收治的468例病理确诊为口咽癌的原发肿瘤患者进行回顾性分析。分析了继发性原发肿瘤的临床特征和预后。结果:在468例初诊口咽癌患者中,222例为P16阴性。中位随访时间为64.3个月,66例发生了二次原发癌,发生率为29.3%,其中63.6%(42/66)为同步癌,36.4%(42/66)为二次原发癌。为同步癌,36.4%(24/66)食管是最常见的受累部位。p16阴性口咽癌伴同步第二原发癌、无第二原发癌和异质第二原发癌的5年生存率分别为26.3%、57.3%和73.2%(P=0.001);第二原发癌占全组死亡人数的11.2%(12/107)。第二原发癌占全组死亡人数的11.2%(12/107),其中异型第二原发癌占75.0%(9/12)。P16阳性患者246例,中位随访时间52.4个月,20例患者出现第二原发癌(8.1%)。其中,65.0%(13/20)为同步癌,35.0%(7/20)为异时性。食管是最常见的受累部位。p16阳性的同步、异质和非第二原发癌组的4年生存率分别为51.9%、80.7%和83.3%。继发性原发癌占p16阳性患者死亡总数的3.8%(2/52)。P16阳性组的死亡人数占总死亡人数的3.8%(2/52)。结论:p16 阳性和阴性口咽癌的二次原发癌发生率不同。无论 p16 状态如何,食管都是最常受累的部位。无论p16状态如何,同步第二原发癌患者的生存率均低于无第二原发癌的患者。对于p16阴性口咽癌,异质性第二原发癌患者的预后较好,第二原发癌是导致死亡的主要原因之一。
{"title":"[Clinical characteristics and efficacy of oropharyngeal carcinoma with secondary primary tumor].","authors":"Meilin He, Runye Wu, Ye Zhang, Xiaodong Huang, Kai Wang, Xuesong Chen, Jingbo Wang, Yuan Qu, Jingwei Luo, Junlin Yi","doi":"10.13201/j.issn.2096-7993.2023.09.007","DOIUrl":"10.13201/j.issn.2096-7993.2023.09.007","url":null,"abstract":"<p><p><b>Objective:</b>To analysis the clinical features and prognosis in oropharyngeal carcinoma with secondary primary tumor. <b>Methods:</b>A retrospective analysis was performed on 468 pathologically confirmed oropharyngeal cancer as the primary tumor patients with p16 status, excluded distant metastasis, and admitted to the Chinese Academy of Medical Sciences from January 2010 to December 2020. The clinical features and prognosis of the secondary primary tumor were analyzed. <b>Results:</b>Among 468 patients with oropharyngeal cancer treated at initial diagnosed, 222 cases were P16-negative. With a median follow-up time of 64.3 months, 66 cases developed second primary cancer, with an incidence of 29.3%, among which 63.6%(42/66) were synchronous and 36.4%(24/66) were heterochronous, esophagus was the most commonly involved site. The 5-year OS of p16-negative oropharyngeal carcinoma with synchronous second primary cancer, without second primary cancer and with heterogeneous second primary cancer were 26.3% and 57.3% and 73.2%(<i>P</i>=0.001); The second primary cancer accounted for 11.2%(12/107) of the deaths in the whole group, among them, the heterochronous second primary accounted for 75.0%(9/12). There were 246 patients with p16 positive, with a median follow-up time of 52.4 months, 20 patients developed second primary cancer(8.1%). Among them, 65.0%(13/20) were synchronous and 35.0%(7/20) were heterochronous. Esophagus was the most commonly involved site. The 4-year OS of p16-positive with synchronous, heterochronous and non-second primary cancer group were 51.9%, 80.7% and 83.3%. Secondary primary cancer accounted for 3.8%(2/52) of all deaths in p16 positvie group. <b>Conclusion:</b>The incidence of second primary cancer of p16 positive and negative oropharyngeal carcinoma were different. The esophagus was the most commonly involved site regardless of p16 status. Regardless of p16 status, the survival of patients with synchronous second primary cancer was worse than those without second primary cancer. For p16-negative oropharyngeal carcinoma, the prognosis was better in patients with heterogeneous second primary cancer, the second primary cancer is one of the main causes of death.</p>","PeriodicalId":18104,"journal":{"name":"Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology, head, and neck surgery","volume":"37 9","pages":"721-728"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10722119/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10120008","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[A case of sinonasal inverted papilloma with malignant transformation and distant metastasis: a 10-year follow-up report]. [一例伴有恶性转化和远处转移的鼻窦倒置乳头状瘤:10 年随访报告]。
Q4 Medicine Pub Date : 2023-09-01 DOI: 10.13201/j.issn.2096-7993.2023.09.013
Haiyan Li, Xiang Zhai

Sinonasal inverted papilloma(SNIP) is a kind of benign tumor originating from the nasal cavity and paranasal sinuses, accounting for 70% of papillomas. The incidence of the disease is more common in males, with an average age of 50-60 years. It is most likely to occur in unilateral maxillary sinus and ethmoid sinus, followed by sphenoid sinus and frontal sinus.It has the characteristics of local invasion, high recurrence rate and malignant tendency, and most malignant transformation into squamous cell carcinoma. Endoscopic nasal resection and appropriate adjuvant therapy can help to reduce the recurrence rate and inhibit further deterioration. We report the results of a 10-year follow-up of a SNIP patient, including the clinical manifestations, recurrence course and treatment plan during the 10 years. The patient underwent multiple nasal endoscopic surgeries, and had a recurrence of multiple focal attachment pattern, and finally had direct invasion and distant metastasis. Tumor recurrence and further deterioration persisted despite the use of a comprehensive treatment.

鼻窦倒置乳头状瘤(SNIP)是一种起源于鼻腔和副鼻窦的良性肿瘤,占乳头状瘤的 70%。男性发病率较高,平均年龄为 50-60 岁。最易发生于单侧上颌窦和乙状窦,其次是蝶窦和额窦,具有局部浸润、复发率高、恶变倾向强等特点,恶变为鳞状细胞癌者居多。鼻内镜切除术和适当的辅助治疗有助于降低复发率,抑制病情进一步恶化。我们报告了一名 SNIP 患者的 10 年随访结果,包括 10 年间的临床表现、复发过程和治疗方案。该患者接受了多次鼻内窥镜手术,多处病灶附着模式复发,最后出现直接侵犯和远处转移。尽管采用了综合治疗,但肿瘤复发和病情进一步恶化的情况依然存在。
{"title":"[A case of sinonasal inverted papilloma with malignant transformation and distant metastasis: a 10-year follow-up report].","authors":"Haiyan Li, Xiang Zhai","doi":"10.13201/j.issn.2096-7993.2023.09.013","DOIUrl":"10.13201/j.issn.2096-7993.2023.09.013","url":null,"abstract":"<p><p><b></b> Sinonasal inverted papilloma(SNIP) is a kind of benign tumor originating from the nasal cavity and paranasal sinuses, accounting for 70% of papillomas. The incidence of the disease is more common in males, with an average age of 50-60 years. It is most likely to occur in unilateral maxillary sinus and ethmoid sinus, followed by sphenoid sinus and frontal sinus.It has the characteristics of local invasion, high recurrence rate and malignant tendency, and most malignant transformation into squamous cell carcinoma. Endoscopic nasal resection and appropriate adjuvant therapy can help to reduce the recurrence rate and inhibit further deterioration. We report the results of a 10-year follow-up of a SNIP patient, including the clinical manifestations, recurrence course and treatment plan during the 10 years. The patient underwent multiple nasal endoscopic surgeries, and had a recurrence of multiple focal attachment pattern, and finally had direct invasion and distant metastasis. Tumor recurrence and further deterioration persisted despite the use of a comprehensive treatment.</p>","PeriodicalId":18104,"journal":{"name":"Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology, head, and neck surgery","volume":"37 9","pages":"759-764"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10722118/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10474875","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Comparison of different laryngeal preservation strategies based on chemoradiotherapy in locally advanced hypopharyngeal carcinoma]. [局部晚期下咽癌化疗基础上的不同保喉策略比较]。
Q4 Medicine Pub Date : 2023-09-01 DOI: 10.13201/j.issn.2096-7993.2023.09.005
Xi Luo, Shiran Sun, Yi Xu, Xiaodong Huang, Kai Wang, Runye Wu, Jingbo Wang, Ye Zhang, Jianghu Zhang, Xuesong Chen, Yuan Qu, Jingwei Luo, Junlin Yi

Objective:This study aimed to evaluate the clinical features and treatment outcomes of the value of response-adapted treatment following radiotherapy and induction chemotherapy follwing subsequent comprehensive therapy in patients with resectable locally advanced hypopharyngeal carcinoma. Methods:This cohort study was conducted from September 2010 to September 2020 in our hospital, 231 patients pathologically confirmed stage Ⅲ and ⅣB resectable locally advanced hypopharyngeal carcinoma included. For the IC-directed ART strategy, IC is used to select good candidates to receive radical RT or CCRT, and others undergo surgery. He response-adapted strategy was determined based on the primary tumor response, which was evaluated at a dose of 50 Gy. If the response reached complete response or partial response(more than 80% tumor regression), patients received radical RT or CCRT; otherwise, they received surgery, if possible, at 4 to 6 weeks after RT. The end points of the study were OS(overall survival), progression free survival(PFS), locoregional recurrence-free survival(LRRFS) and LDFS. Results:In IC-directed group, 75.0%(57/76) patients reached PR after 2 cycles of induction chemotherapy. While in RT-directed group, 70.3%(109/155) patients reached large PR at dose of 50 Gy. The median interquartile range follow-up period of the whole cohort was 63.8 months. The 5-year OS, PFS, LRRFS and SFL of the whole cohort were 47.9%、39.6%、44.3% and 36.2%, respectively. In evaluations based on the different treatment strategies, the 5-year OS and SFL were 51.3% versus 37.0%(HR 0.67; 95%CI 0.43-1.05; P=0.07) and 27.8% versus 39.8%(HR 0.68; 95%CI 0.46-0.99; P=0.04) between IC-directed and RT-directed groups. In additional, surgery complications did not significantly differ between these two groups. Conclusion:In this cohort study, the response-adapted strategy based on an early RT response facilitated better treatment tailoring, and higher laryngeal preservation compared with IC-directed strategies. This approach could provide a feasible laryngeal preservation strategy in patients with resectable locally advanced hypopharyngeal carcinoma.

目的:本研究旨在评估可切除的局部晚期下咽癌患者在放疗和诱导化疗后接受反应适应性治疗的临床特征和治疗效果。方法:该队列研究于2010年9月至2020年9月在我院进行,共纳入231例经病理证实的Ⅲ期和ⅣB期可切除局部晚期下咽癌患者。在IC引导的ART策略中,利用IC选择好的候选者接受根治性RT或CCRT,其他人接受手术。他的反应适应策略是根据原发肿瘤反应确定的,以50 Gy的剂量进行评估。如果反应达到完全反应或部分反应(肿瘤消退超过80%),患者将接受根治性RT或CCRT治疗;否则,如果可能,患者将在RT治疗后4至6周接受手术治疗。研究终点为OS(总生存期)、无进展生存期(PFS)、无局部复发生存期(LRRFS)和LDFS。和 LDFS。结果:在IC导向组中,75.0%(57/76)的患者在2个周期的诱导治疗后达到PR。患者在两个周期的诱导化疗后达到PR。而在RT导向组中,70.3%(109/155)而在RT引导组中,70.3%(109/155)的患者在剂量为50 Gy时达到大PR。整个组群的中位四分位距随访时间为63.8个月。全组患者的5年OS、PFS、LRRFS和SFL分别为47.9%、39.6%、44.3%和36.2%。在基于不同治疗策略的评估中,5年OS和SFL分别为51.3%对37.0%(HR 0.67; 95%CI 0.43-1.05; P=0.07)和27.8%对39.0%(HR 0.67; 95%CI 0.43-1.05; P=0.07)。和27.8%对39.8%(HR 0.68; 95%CI 0.46-0.99; P=0.04)。在IC引导组和RT引导组之间的差异也不大。此外,手术并发症在两组之间没有明显差异。结论:在这项队列研究中,与IC导向策略相比,基于早期RT反应的反应适应策略能更好地调整治疗方案,保留更多喉部。这种方法可为可切除的局部晚期下咽癌患者提供一种可行的保喉策略。
{"title":"[Comparison of different laryngeal preservation strategies based on chemoradiotherapy in locally advanced hypopharyngeal carcinoma].","authors":"Xi Luo, Shiran Sun, Yi Xu, Xiaodong Huang, Kai Wang, Runye Wu, Jingbo Wang, Ye Zhang, Jianghu Zhang, Xuesong Chen, Yuan Qu, Jingwei Luo, Junlin Yi","doi":"10.13201/j.issn.2096-7993.2023.09.005","DOIUrl":"10.13201/j.issn.2096-7993.2023.09.005","url":null,"abstract":"<p><p><b>Objective:</b>This study aimed to evaluate the clinical features and treatment outcomes of the value of response-adapted treatment following radiotherapy and induction chemotherapy follwing subsequent comprehensive therapy in patients with resectable locally advanced hypopharyngeal carcinoma. <b>Methods:</b>This cohort study was conducted from September 2010 to September 2020 in our hospital, 231 patients pathologically confirmed stage Ⅲ and ⅣB resectable locally advanced hypopharyngeal carcinoma included. For the IC-directed ART strategy, IC is used to select good candidates to receive radical RT or CCRT, and others undergo surgery. He response-adapted strategy was determined based on the primary tumor response, which was evaluated at a dose of 50 Gy. If the response reached complete response or partial response(more than 80% tumor regression), patients received radical RT or CCRT; otherwise, they received surgery, if possible, at 4 to 6 weeks after RT. The end points of the study were OS(overall survival), progression free survival(PFS), locoregional recurrence-free survival(LRRFS) and LDFS. <b>Results:</b>In IC-directed group, 75.0%(57/76) patients reached PR after 2 cycles of induction chemotherapy. While in RT-directed group, 70.3%(109/155) patients reached large PR at dose of 50 Gy. The median interquartile range follow-up period of the whole cohort was 63.8 months. The 5-year OS, PFS, LRRFS and SFL of the whole cohort were 47.9%、39.6%、44.3% and 36.2%, respectively. In evaluations based on the different treatment strategies, the 5-year OS and SFL were 51.3% versus 37.0%(<i>HR</i> 0.67; 95%<i>CI</i> 0.43-1.05; <i>P</i>=0.07) and 27.8% versus 39.8%(<i>HR</i> 0.68; 95%<i>CI</i> 0.46-0.99; <i>P</i>=0.04) between IC-directed and RT-directed groups. In additional, surgery complications did not significantly differ between these two groups. <b>Conclusion:</b>In this cohort study, the response-adapted strategy based on an early RT response facilitated better treatment tailoring, and higher laryngeal preservation compared with IC-directed strategies. This approach could provide a feasible laryngeal preservation strategy in patients with resectable locally advanced hypopharyngeal carcinoma.</p>","PeriodicalId":18104,"journal":{"name":"Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology, head, and neck surgery","volume":"37 9","pages":"708-714"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10722127/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10175353","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology, head, and neck surgery
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1